SITUS JUDI MBL77 - AN OVERVIEW

In addition to ibrutinib, patients with M-CLL, devoid of TP53 aberrations and suit ample to tolerate FCR therapy, may still be very good candidates for that latter, With all the advantage staying this treatment may be concluded in 6 months whilst ibrutinib need to be taken indefinitely. This feature could be particularly precious for non-compliant